Juniper investment company buys $2.73m in Orthofix shares

Juniper Investment Company, a significant 10% stakeholder and director of Orthofix Medical Inc., recently made a substantial investment in the company's shares. On September 18, 2026, the investment firm purchased 120,000 shares at an average cost of $8.7393 per share, valuing the transactions at around $1.05 million. A second acquisition followed on September 21, 2026, with the firm buying an additional 190,000 shares at an average price of $8.8599 per share, amounting to approximately $1.68 million in total.

This strategic move proved fruitful, as Orthofix Medical's stock price surged from the purchase price to a current rate of $9.44, resulting in an 8.4% return over the past week. Analysts posit that Orthofix remains undervalued, with a Fair Value of $12.89, placing it among promising opportunities in the medical device sector. Juniper Investment Company now holds a total of 4,792,043 shares of Orthofix common stock, with 3,771,216 shares managed through its Targeted Opportunity Fund, L.P., 84,926 shares through the Multi-Strategy Fund, L.P., and 935,901 shares through the Targeted Opportunities, L.P.

These shares are managed by Juniper Investment Company, which disclaims beneficial ownership beyond its financial interest. Despite recent challenges in smaller U.S. spine distributors, Orthofix reported robust second-quarter 2026 results, surpassing expectations with increased revenue and earnings. Stifel maintained its Buy rating and price target of $13.00 on Orthofix Medical shares, citing profitable growth and an attractive valuation.